X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4591) 4591
Publication (302) 302
Book Review (36) 36
Book Chapter (22) 22
Magazine Article (11) 11
Dissertation (4) 4
Conference Proceeding (3) 3
Newsletter (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3561) 3561
male (2380) 2380
hypertriglyceridemia (2167) 2167
female (2089) 2089
index medicus (1765) 1765
middle aged (1642) 1642
adult (1544) 1544
triglycerides - blood (1348) 1348
hypertriglyceridemia - drug therapy (1091) 1091
risk factors (998) 998
hypertriglyceridemia - blood (929) 929
triglycerides (898) 898
aged (795) 795
cholesterol (768) 768
hypertriglyceridemia - complications (768) 768
hyperlipidemia (615) 615
lipids (614) 614
animals (613) 613
hypolipidemic agents - therapeutic use (585) 585
endocrinology & metabolism (555) 555
cholesterol - blood (482) 482
metabolism (479) 479
insulin resistance (471) 471
lipoproteins (463) 463
cholesterol, hdl - blood (450) 450
risk (434) 434
lipids - blood (415) 415
pharmacology & pharmacy (414) 414
atherosclerosis (411) 411
diabetes (411) 411
metabolic syndrome (404) 404
treatment outcome (396) 396
medicine, general & internal (390) 390
hypertriglyceridemia - therapy (388) 388
hypertriglyceridemia - chemically induced (383) 383
obesity (378) 378
cardiac & cardiovascular systems (355) 355
dyslipidemia (355) 355
cardiovascular-disease (354) 354
pancreatitis (354) 354
cholesterol, ldl - blood (353) 353
hypertriglyceridemia - etiology (345) 345
research (338) 338
insulin-resistance (336) 336
nutrition & dietetics (330) 330
coronary-heart-disease (320) 320
care and treatment (318) 318
health aspects (308) 308
peripheral vascular disease (306) 306
insulin (301) 301
hypercholesterolemia (299) 299
cardiovascular disease (290) 290
adolescent (287) 287
hypertriglyceridemia - epidemiology (286) 286
rats (285) 285
prevalence (276) 276
glucose (268) 268
therapy (266) 266
diet (265) 265
plasma (264) 264
disease (263) 263
body mass index (258) 258
hypertriglyceridemia - metabolism (250) 250
triglyceride (250) 250
biochemistry & molecular biology (249) 249
hypertriglyceridemia - diagnosis (248) 248
lipoproteins - blood (245) 245
diabetes mellitus (238) 238
double-blind method (237) 237
hypertension (234) 234
physiological aspects (228) 228
cardiovascular diseases (223) 223
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (218) 218
young adult (213) 213
diabetes mellitus, type 2 - complications (211) 211
acute disease (205) 205
fatty acids (204) 204
analysis (203) 203
mortality (203) 203
mice (201) 201
risk-factors (201) 201
medicine & public health (199) 199
cardiovascular (196) 196
diabetes mellitus, type 2 - blood (196) 196
hypertriglyceridemia - genetics (196) 196
pancreatitis - etiology (195) 195
retrospective studies (195) 195
blood glucose - metabolism (194) 194
drug therapy, combination (193) 193
myocardial-infarction (190) 190
triglycerides - metabolism (185) 185
fatty acids, omega-3 - therapeutic use (184) 184
lipoprotein lipase (182) 182
time factors (182) 182
heart-disease (178) 178
hypercholesterolemia - drug therapy (178) 178
type 2 diabetes (178) 178
biomarkers - blood (177) 177
child (176) 176
low-density-lipoprotein (174) 174
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4252) 4252
German (91) 91
French (67) 67
Spanish (66) 66
Japanese (62) 62
Italian (21) 21
Russian (18) 18
Polish (15) 15
Korean (14) 14
Portuguese (14) 14
Chinese (10) 10
Dutch (8) 8
Hungarian (6) 6
Czech (5) 5
Norwegian (4) 4
Finnish (3) 3
Croatian (2) 2
Hebrew (2) 2
Turkish (2) 2
Danish (1) 1
Icelandic (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 07/2018, Volume 72, Issue 3, pp. 330 - 343
Despite the important role of high-intensity statins in reducing atherosclerotic cardiovascular disease events in secondary and primary prevention, substantial... 
hypertriglyceridemia | dyslipidemia and residual risk | clinical trials | omega-3 fatty acids | RANDOMIZED CONTROLLED-TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | GLOBAL HEALTH OUTCOMES | LOW-DENSITY-LIPOPROTEIN | PURIFIED EICOSAPENTAENOIC ACID | OF-FUNCTION MUTATIONS | AMERICAN-HEART-ASSOCIATION | ESTER AMR101 THERAPY | AIM-HIGH TRIAL | LOW HDL/HIGH TRIGLYCERIDES | CORONARY-ARTERY-DISEASE | Hypertriglyceridemia - drug therapy | Dyslipidemias - drug therapy | Cardiovascular Diseases - metabolism | Cardiovascular Diseases - prevention & control | Humans | Lipid Metabolism - drug effects | Dyslipidemias - metabolism | Hypertriglyceridemia - metabolism | Hypolipidemic Agents - pharmacology | Atherosclerosis - metabolism | Atherosclerosis - prevention & control | Type 2 diabetes | Medical research | Medical colleges | C-reactive protein | Hyperlipidemia | Low density lipoproteins | Triglycerides | Apolipoproteins | Niacin | Coronary heart disease | Epidemiology | Cardiovascular agents | Unsaturated fatty acids | Medicine, Experimental | Statins | Omega-3 fatty acids | Atherogenesis | Heart attacks | Dyslipidemia | Clinical trials | Risk | Lipids | Cardiovascular disease | Metabolic syndrome | Density | Optimization | Proteins | Vitamin B | Atherosclerosis | Cholesterol ester transfer protein | Diabetes mellitus (non-insulin dependent) | Obesity | Stability | Risk groups | Diabetes mellitus | Health risks | Inflammation | Fatty acids | Low density lipoprotein | Cholesterol | Disease prevention | Hypertriglyceridemia | Arteriosclerosis | Insulin resistance | Diabetes | Cardiovascular diseases | Metabolic disorders
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Clinical Cardiology, ISSN 0160-9289, 01/2018, Volume 41, Issue 1, pp. 13 - 19
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2016, Volume 119, Issue 3, pp. 410 - 415
High triglyceride (TG) levels among patients with type 2 diabetes mellitus (DM) are associated with higher medical costs. We analyzed the economic impact of... 
Cardiovascular | CARE COSTS | GEMFIBROZIL | HEART-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | ACUTE-CORONARY-SYNDROME | EVENTS | MEN | PREVENTION | ADULTS | RISK | Hypertriglyceridemia - drug therapy | Fibric Acids - therapeutic use | Humans | Middle Aged | Diabetes Mellitus, Type 2 - economics | Male | Hypercholesterolemia - drug therapy | Niacin - therapeutic use | Cholesterol, LDL - blood | Female | Hypertriglyceridemia - economics | Retrospective Studies | Drug Therapy, Combination | Diabetes Mellitus, Type 2 - complications | Hypercholesterolemia - economics | Health Care Costs | Hypertriglyceridemia - complications | Cost-Benefit Analysis | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cholesterol, HDL - blood | Fatty Acids, Omega-3 - therapeutic use | Hypercholesterolemia - complications | Aged | Hypolipidemic Agents - therapeutic use | Cohort Studies | Type 2 diabetes | Health maintenance organizations | Diabetics | Analysis | Triglycerides | Statins | Cholesterol | Cardiovascular agents | Medical care, Cost of | Diabetes therapy | Heart failure | Costs | Review boards | Medical records | Clinical trials | Cardiovascular disease | Lipids | Low density lipoprotein | Alcohol use | Studies | Body mass index | Algorithms | Pharmacy | Diabetes | Kidney diseases | Drug therapy | Acute coronary syndromes | Electronic health records
Journal Article
Journal of infectious diseases, ISSN 0022-1899, 2017, Volume 216, Issue 4, pp. 436 - 446
Journal Article